In vivo measurements of frequency-dependent attenuation in tumors of the liver.
Ultrasonic frequency-dependent attenuation (FDA) coefficients of the liver obtained from selected regions of interest within the liver were determined in 106 individuals, 40 cases presumed normal based on medical histories and 66 with malignant tumors (hepatocellular carcinoma [HCC] or metastatic liver tumor) or benign tumors (hepatic hemangioma, hepatic adenoma, or focal nodular hyperplasia of the liver). All liver tumors were confirmed histopathologically by ultrasonically guided fine-needle biopsy and/or operation. Mean attenuation of normal liver was 0.53 +/- 0.03 dB/cm/MHz, 0.29 +/- 0.05 dB/cm/MHz in hepatic hemangioma, 0.43 +/- 0.05 dB/cm/MHz in HCC, and 0.41 +/- 0.12 dB/cm/MHz in metastatic liver tumor. Hepatic adenoma and focal nodular hyperplasia of the liver produced higher values, averaging 0.66 +/- 0.09 dB/cm/MHz. This difference between malignant and benign tumors was statistically significant. There was some correlation between the FDA for the hepatic tumor and the histopathology that merits further investigation.